You are here

FDA Guidance for Clinical Trials during COVID-19

Recognizing the importance of cancer treatment and treatment on clinical trials in the presence of COVID-19, the FDA has issued guidance to help ensure that patients can continue their therapy. Oncology research centers are continuing to respond to COVID-19 precautions while keeping patient safety as the top priority. As changes to patient care are made, treatment teams will be communicating any new information to patients and caregivers.

During this time, the SARC Operations Office has moved 100% remote to comply with Michigan’s Shelter-In-Place order.  Fortunately, we are positioned to work remote seamlessly.  We continue to provide support to our sarcoma centers engaged in SARC research.  Some centers are curtailing clinical trial accrual.  If you have questions about a specific clinical trial or sarcoma research please do not hesitate to reach out at sarc@sarctrials.org